May 21, 2020 / 12:34 PM / 7 days ago

BRIEF-I-Mab, Genexine Report China NMPA Clearance For Phase 2 Glioblastoma Multiforme Clinical Trial

May 21 (Reuters) - I-Mab:

* I-MAB AND GENEXINE ANNOUNCE CHINA NMPA CLEARANCE FOR PHASE 2 CLINICAL TRIAL OF TJ107/HYLEUKIN-7™ IN GLIOBLASTOMA MULTIFORME

* I-MAB - FINANCIAL TERMS ARE NOT DISCLOSED

* I-MAB - I-MAB WILL BE MAINLY RESPONSIBLE FOR CONDUCTING PHASE 2 GBM CLINICAL TRIAL IN CHINA

* I-MAB - GENEXINE WILL SHARE DEVELOPMENT STRATEGIES, DATA AND COSTS FOR SUCCESS OF THIS CLINICAL TRIAL

* I-MAB - I-MAB AND GENEXINE EXPAND COLLABORATION FOR DEVELOPMENT OF TJ107/HYLEUKIN-7™ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below